

# Computational analysis of naturally occurring resistance-associated substitutions in genes *NS3*, *NS5A*, and *NS5B* among 86 subtypes of hepatitis C virus worldwide

This article was published in the following Dove Press journal:  
*Infection and Drug Resistance*

Ruihong Wu<sup>1</sup>  
Dongfeng Geng<sup>2</sup>  
Xiumei Chi<sup>1</sup>  
Xiaomei Wang<sup>1</sup>  
Xiuzhu Gao<sup>1</sup>  
Hongqin Xu<sup>1</sup>  
Ying Shi<sup>1</sup>  
Yazhe Guan<sup>1</sup>  
Yang Wang<sup>1</sup>  
Jinglan Jin<sup>1</sup>  
Yanhua Ding<sup>3</sup>  
Junqi Niu<sup>1</sup>

<sup>1</sup>Department of Hepatology, First Hospital of Jilin University, Changchun, Jilin Province 130021, People's Republic of China; <sup>2</sup>Centre for Reproductive Medicine, Centre for Prenatal Diagnosis, First Hospital of Jilin University, Changchun, Jilin Province 130021, People's Republic of China; <sup>3</sup>Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin Province 130021, People's Republic of China

Correspondence: Yanhua Ding  
Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin Province 130021, People's Republic of China  
Tel +86 4 318 878 2168  
Email dingyanhua2003@126.com

Junqi Niu  
Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin Province 130021, People's Republic of China  
Tel +86 4 318 187 5101  
Email junqiniu@aliyun.com

**Background and objective:** Direct-acting antivirals (DAA) facing resistance continue to be used in some areas worldwide. Thus, identifying hepatitis C virus (HCV) genotypes/subtypes and loci with certain prevalent resistance-associated substitutions (RASs) deserves attention. We investigated the global and regional frequencies of naturally occurring RASs among all confirmed HCV subtypes ( $n=86$ ) and explored co-occurring and mutually exclusive RAS pairs within and between genes *NS3*, *NS5A*, and *NS5B*.

**Methods:** A total of 213,908 HCV sequences available as of July 10, 2019 were retrieved from the NCBI nucleotide database. After curation, 17,312 *NS3*, 8,478 *NS5A*, and 25,991 *NS5B* sequence fragments from DAA-naïve patients were screened for RASs. MEGA 6.0 was used to translate aligned nucleotide sequences into amino acid sequences, and RAS pairs were identified by hypergeometric analysis.

**Results:** RAS prevalence varied significantly among HCV subtypes. For example, D168E, highly resistant to all protease inhibitors except voxilaprevir, was nearly absent in all subtypes except in 43.48% of GT5a sequences. RASs in *NS3* exhibiting significantly different global distribution included Q80K in GT1a with the highest frequency in North America (54.49%), followed by in Europe (22.66%), Asia (6.98%), Oceania (6.62%), and South America (1.03%). The prevalence of *NS3* S122G in GT1b was highest in Asia (26.6%) and lowest in Europe (2.64%). *NS5A* L28M, R30Q, and Y93H in GT1b, L31M in GT2b, and *NS5B* C316N in GT1b was most prevalent in Asia. A150V in GT3a, associated with sofosbuvir treatment failure, was most prevalent in Asia (44.09%), followed by Europe (31.19%), Oceania (24.29%), and North America (19.05%). Multiple mutually exclusive or co-occurring RAS pairs were identified, including Q80K+R155K and R155K+D168G in GT1a and L159F+C316N and R30Q (*NS5A*)+C316N (*NS5B*) in GT1b.

**Conclusion:** Our data may be of special relevance for those countries where highly effective antivirals might not be available. Considering the specific RASs prevalence will help the clinicians to make optimal treatment choices. The RASs pairs would benefit anti-HCV drug development.

**Keywords:** hepatitis C virus, direct-acting antiviral, resistance-associated substitution, subtype

## Introduction

Infection with hepatitis C virus (HCV) is a global public health problem. Between 130 and 170 million people are HCV chronically infected<sup>1</sup> and up to 4 million individuals are newly infected with HCV annually.<sup>2</sup> Persistent HCV infection induces

high risk for developing severe liver diseases, such as liver cirrhosis and hepatocellular carcinoma.<sup>2,3</sup> HCV is an enveloped positive-sense single-stranded RNA virus whose replication can be robust; model-based calculations indicate production of  $10^{12}$  virions/day.<sup>4,5</sup> This high-level replication and a lack of viral RNA polymerase proofreading contribute to HCV's genetic divergence. The virus is currently classified into seven major genotypes and 86 subtypes according to the International Committee on Taxonomy of Viruses (June 2017) ([https://talk.ictvonline.org/ictv\\_wikis/flaviviridae/w/sg\\_flavi/56/hcv-classification](https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification)) with ~30% divergence at the genotype level and ~15% divergence at the subtype level.<sup>6</sup> HCV clearance, which is associated with reduced rates of de novo hepatocellular carcinoma,<sup>7</sup> is strongly dependent on HCV genotype/subtype when induced by interferon-based antiviral therapy with sustained virologic response (SVR) rates of approximately 50–80%.<sup>8–10</sup>

HCV therapy has been revolutionized with the advent of direct-acting antivirals (DAA) that directly target HCV gene products, including NS3 protease inhibitors, NS5A inhibitors, nucleos(t)ide inhibitors (NI), and non-nucleoside inhibitors (NNI) of the NS5B RNA-dependent RNA polymerase.<sup>11</sup> Generally, DAA based regimens yield highly promising SVR rates (>90%). However, virologic failure still occurs and has been associated with the emergence of HCV variants with resistance-associated substitutions (RASs), which impair drug susceptibility. Notably, RASs can occur naturally in a genotype/subtype-dependent manner before DAA-induced selective pressure occurs.<sup>12–17</sup> For example, the SVR rate of daclatasvir/asunaprevir was severely attenuated due to baseline RASs (65.4% with RASs vs 94.3% without RASs).<sup>18</sup> Moreover, due to the negative effects of RAS Q80K on the efficacy of simeprevir, clinical guidelines recommend pre-treatment screening in patients infected with HCV subtype GT1a.<sup>19,20</sup> Thus, assessing the prevalence of naturally occurring RASs in different HCV genotypes/subtypes and determining their global geographic distribution will help optimize the selection of therapeutic regimens.

Several studies have assessed the prevalence of naturally occurring RASs in HCV genes NS3, NS5A, and/or NS5B from DAA-naïve patients but have focused on particular subtypes<sup>21–25</sup> or have used HCV sequence databases<sup>26–28</sup> containing a relatively small number of sequences covering very few subtypes. Welzel et al<sup>29</sup> performed the largest study to date including 46 subtypes across 5 geographic regions, but the RAS distributions

determined in that study were based on clinical trials from regional medical centers in primarily developed countries and thus may not reflect the global HCV RAS landscape.

To address this knowledge gap, the aims of our current study were to (1) investigate the global and regional prevalence of HCV RASs among all confirmed HCV subtypes (n=86) by mining HCV sequences in NCBI nucleotide database and Los Alamos HCV database, (2) explore the RASs pairs showing significant more or less co-occurrence.

## Materials and methods

### HCV datasets

HCV genomic sequences available as of July 10, 2019 were retrieved from the NCBI nucleotide database (<https://www.ncbi.nlm.nih.gov/nucleotide>) in GenBank (full) format using the following searching criteria: the title contained the words “hepatitis C virus” and the organism was “hepatitis C virus”. The following information was extracted for each sequence: accession number, times of sampling and publication, HCV genotype/subtype, geographic region, and treatment. If the above-mentioned parameters were not available, we extracted the information from publications linked with the sequences. A total of 213,908 HCV genomic sequences were ultimately retrieved. Only one sequence from any duplicate sets and the sequence obtained from the last visit for patients with multiple visits was retained for further analysis. Sequence exclusion criteria were as follows: (1) no NS3, NS5A, or NS5B fragments present; (2) low quality; (3) from non-human hosts; (4) different clone sequences from the same patient; (5) sequences that encoded non-functional proteins; (6) sequences without any available subtype information or with mixed-genotypes; (7) groups of sequences with ambiguous DAA treatment information (eg, “some DAA-treated patients”) that did not specify which patients/sequences were DAA-treated; and (8) sequences from DAA-treated patients. Sequences were confirmed to be from DAA-treated patients based on the NCBI database description and/or the linked publications. Finally, 17,312 NS3, 8,478 NS5A, and 25,991 NS5B sequences were retained for further analysis.

All nucleotide sequences were aligned using the Los Alamos HCV Database (LANL; <http://hcv.lanl.gov/components/sequence/HCV/search/searchi.html>), which also provided curated HCV subtype and geographic region

information for some sequences. All sequences were aligned against the H77 reference sequence (GenBank accession no. NC\_004102). The aligned nucleotide sequences in FASTA format were downloaded and then translated into their corresponding amino acid sequences with MEGA 6.0 software (Center for Evolutionary Medicine and Informatics, Tempe, AZ, USA) and manually checked and edited as necessary. The MEGA 6.0 output table was further analyzed with R (version 2.10.0) to calculate allele frequencies for each RAS. We focused only on the defined genomic regions relevant to drug resistance, including the first 630 amino acids in NS3, the first 100 amino acids in NS5A, and all 591 amino acids in NS5B.

## RASs

RASs were defined by a combination of substitutions summarized in three review papers,<sup>30–32</sup> and others recently reported associated with DAA treatment failure and/or conferred a  $\geq 2$ -fold change in susceptibility compared with a reference strain via *in vitro* replicon assays.<sup>33–39</sup>

NS3 RASs included V36A/G/L/M, Q41K/R, F43C/I/L/S/V, T54A/S, V55A/I, Y56F/H/N, Q80G/H/K/L/R, S122D/G/N/R/T, S138T, R155C/G/I/K/L/N/Q/S/T/W, A156G/H/K/L/M/S/T/V, V158A, A166T, D168/A/C/E/F/G/H/I/K/L/N/Q/R/S/T/V/Y, I170T/V, and L175M.

NS5A RASs included K24A/E/G/N/Q/R, S24F/H/T, Q24K/T, T24A/S, K26E, M28A/G/I/K/S/T/V, L28A/F/I/M/S/T/V, F28C/M/S/V, Q30D/E/G/H/I/K/L/N/R/S/T/Y, R30C/E/G/H/K/N/Q/S/T, A30G/H/K/V, L30A/F/G/H/Q/R/S, L31F/I/M/P/V/W, M31F/I/L/V, P32A/L/Q/R/S, S38F, Q54H, H58D/L/N, P58A/D/G/L/R/S/T, T58A/D/G/H/L/N/S, E62D/L, A92K/P/T, C92A/K/N/R/S/T, E92K, Y93C/F/H/I/L/N/R/S/T/W, and T93A/H/I/N/S.

NS5B RASs included A150V, L159F, G188D, K206E, E237G, N244I, S282G/R/T, M289I/L, L314H, C316F/H/N/Y, L320F, V321A/I, S368T, A395G, N411S, M414I/T/V, N444K, C445F, E446K/Q, Y448C/H, C451S, A553T/V, G554S, S556G/N/R, G558R, D559G/N, Y561H, and S565F.

## Statistical analysis

Differences in RAS prevalence among geographic regions were determined using Fisher's exact test. Probabilities (*P*-values) of observing a pair of RASs together in no fewer or no greater than *n* sequences by random chance were calculated using the hypergeometric test. Statistical analyses were performed using R (version 2.10.0).

A *P* value  $< 0.05$  was considered to be statistically significant.

## Results

### Prevalence of naturally occurring NS3 RASs in 86 HCV subtypes

The prevalence of naturally occurring NS3 RASs in different HCV subtypes is shown in Table 1. Majority of NS3 RASs were absent or have very low frequencies ( $< 0.5\%$ ), and only several RASs including Q80K, S122G/T/N and D168E were observed in a high rate of sequences in a subtype dependent manner (Figure S1A). The RAS Q80K confers low-level resistance to simeprevir *in vitro* and is associated with a reduced treatment response *in vivo*. We found Q80K-positive sequences in 31.74% of HCV subtype GT1a sequences (2277/7178) but only 1.14% of sequences in subtype GT1b (81/7176). This RAS was found frequently in subtypes GT1d (86.67%, 13/15), 5a (100%, 46/46), and 6a (98.28%, 402/409) but was very rare in subtype 3a (0.24%, 2/820). The RAS was also observed in 16.67% (1/6) of subtype 1i sequences. All GT4 and other GT1, 3, 5, 6, 7 subtypes harbored no Q80K-positive sequences. Q80R, which confers resistance to simeprevir/asunaprevir/faldaprevir, was rarely present in 1a (0.49%, 35/7178), 1b (0.3%, 21/7176), 3i (16.67%, 1/6), 4d (1.45%, 1/69), and 6a (0.24%, 1/409). Similarly, R155K, which carries variants associated with resistance to protease inhibitors such as simeprevir, asunaprevir, paritaprevir, vaniprevir, and faldaprevir, was rarely present in 0.96% (69/7164) of GT1a, 16.67% (1/6) 1h, and 0.25% (2/805) 3a sequences. A156L/T/V, the only RASs conferred high resistance ( $> 100$ -fold) to voxilaprevir (a potent pan-genotypic second generation of protease inhibitor), were not detected except in 1a, and 1b with frequencies  $< 0.05\%$ . The RASs at position D168, highly resistant to all protease inhibitors except voxilaprevir, were rare (approximately 1%) in nearly all HCV subtypes, whereas D168E occurred in 43.48% (20/46) of GT5a sequences. RASs at position 122, which confer resistance to simeprevir, asunaprevir and/or voxilaprevir in GT1a and/or GT1b, was highly prevalent in GT5a (122T, 73.9%), GT6a (122N, 76.3%) and GT1b (122G, 9.34%). S122R (confers resistance to simeprevir and asunaprevir) was exclusively detected in GT2 and with GT2 subtype-specific frequencies (i.e., 100% in 2b, 2c, 2d, 2e, 2f, 2i, 2j, 2l, 2m, 2q and 2t but only 1.89% (1/53) in 2a and 0% in 2r and 2u). These present of these RASs may limit the use of

**Table 1** Prevalence of naturally occurring NS3 RASs in 86 HCV subtypes

Sub-type	No. of seq <sup>a</sup>	V36 AGLM	Q4I KR	F43 CILSV	T54 AS	V55AI	Y56 FHN	Q80 GHKLR
1a	7071, 7180	1.50L, 0.48M, 0.01A/G	0.01R	0.01L, 0.01S	3.02S, 0.01A	2.25A, 1.82I	0.67F, 0.06H	31.74K, 1.14L, 0.49R, 0.01G, 0.01H
1b	6849, 7133	0.96L, 0.03M, 0.01A	0.04R, 0.03K	0.04L	2.01S	0.44A, 0.21I	26F	3.68L, 1.14K, 0.30R, 0.03H, 0.01G
1c	5	.	.	.	.	.	.	.
1d	15	13.33L	.	.	66.7S	.	6.67F	86.67K
1e	15	100L	.	.	100S	6.67I	.	.
1g	5	20L	.	.	80S	.	.	.
1h	6	.	.	.	.	.	.	.
1i	6	16.67L	.	.	.	.	16.7F	16.67K
1j	1	.	.	.	.	.	.	.
1k	1	.	.	.	.	.	11.1F	77.8L
1l	9	22.22L	.	.	.	.	.	.
1m	2	.	.	.	.	.	.	.
1n	2	.	.	.	.	.	50F	50L
2a	53	98.11L	.	.	.	.	3.77F	98.1G, 1.89Q
2b	111	100L	.	.	.	.	3.6F	100G
2c	9, 46	100L	.	.	.	.	100F	100G
2d	1	100L	.	.	.	.	100F	100G
2e	1	100L	.	.	100A	.	100F	100G
2f	2	100L	.	.	.	.	100F	100G
2i	4	100L	.	.	.	.	100F	100G
2j	6	83.3L, 16.7M	.	.	.	.	100F	100G
2k	4	75L	.	.	.	.	75F	75G
2l	4	100L	.	.	.	.	.	100G
2m	4	100L	.	.	.	.	100F	100G
2q	2	100L	.	.	.	.	100F	100G
2r	1	100L	.	.	.	.	100F	100G
2t	1	100L	.	.	.	.	100F	100G
2u	1	100L	.	.	.	.	100F	100G
3a	780, 820	99.6L	.	.	0.24S	0.24I	0.24F	0.24K
3b	138	100L	.	.	1.45S	.	.	.

(Continued)

Table 1 (Continued).

Sub-type	No. of seq <sup>a</sup>	V36 AGLM	Q41 KR	F43 CILSV	T54 AS	V55AI	Y56 FHN	Q80 GHKLR
3d	1	100L	.	.	.	.	.	.
3e	1	100L	.	.	.	.	.	.
3g	2	100L	.	.	.	.	.	.
3h	2	100L	.	.	.	.	.	.
3i	6	100L	.	.	.	.	.	16.67R
3k	2	100L	.	.	.	.	.	.
4a	83, 92	97.8L	.	.	6.52S	.	.	.
4b	2	100L	.	.	.	.	.	.
4c	1, 2	100L	.	.	.	.	.	.
4d	49, 69	100L	.	.	.	.	.	1.45R
4f	11	100L	.	.	.	.	.	.
4g	3	100L	.	.	.	.	.	.
4k	4	100L	.	.	.	.	.	.
4l	3	100L	.	.	.	.	.	.
4m	4, 5	100L	.	.	.	.	.	.
4n	3, 4	100L	.	.	.	.	.	.
4o	4	100L	.	.	.	.	.	.
4p	1	100L	.	.	.	.	.	.
4q	1	100L	.	.	.	.	.	.
4r	6	100L	.	.	.	.	.	.
4s	1	100L	.	.	.	.	.	.
4t	1	100L	.	.	.	.	.	.
4v	4	100L	.	.	.	.	.	.
4w	2	100L	.	.	.	.	.	.
5a	46	100L	.	.	.	.	100F	100K
6a	409	.	.	.	.	.	0.73F	98.28K, 0.24L, 0.24R
6b	2	.	.	.	.	.	.	.
6c	2	.	.	.	.	.	.	.
6d	1, 2	50L	.	.	.	.	.	.
6e	10	.	.	.	.	.	.	.

(Continued)

Table 1 (Continued).

Sub-type	No. of seq <sup>a</sup>	V36 AGLM	Q4I KR	F43 CILSV	T54 AS	V55AI	Y56 FHN	Q80 GHKLR
6f	22	100L	.	.	.	.	.	.
6g	2	100L	.	.	.	.	.	.
6h	5	.	.	.	.	.	.	.
6i	3	.	.	.	.	.	.	.
6j	3	.	.	.	.	.	.	.
6k	8	12.5L	.	.	.	.	.	.
6l	8, 9	11.11L	.	.	.	.	.	.
6m	4	.	.	.	.	.	.	.
6n	25	.	.	.	.	.	.	.
6o	3	.	.	.	.	.	.	.
6p	2	.	.	.	.	.	.	.
6q	3	.	.	.	.	.	.	.
6r	3	.	.	.	.	.	66.7F	.
6s	3	100L	.	.	.	.	100F	.
6t	4	100L	.	.	.	.	50F	.
6u	3	.	.	.	.	.	.	.
6v	6	.	.	.	.	.	.	.
6w	3	100L	.	.	.	.	100F	.
6xa	3	.	.	.	.	.	.	.
6xb	2	.	.	.	.	.	.	.
6xc	1	.	.	.	.	.	.	.
6xd	3	100L	.	.	.	.	.	33.3L
6xe	2	.	.	.	.	.	.	.
6xf	2	50L	.	.	.	.	.	.
7a	2	100L	.	.	.	.	.	.
7b	1	100L	.	.	100S	.	.	.

(Continued)

Table 1 (Continued).

Sub-type	S122 DGNRT	R155 CGIKLNQSTW	A156 GHKLMSTV	V158A	A166T	D168 Anyone	I170 TV	L175M
1a	6.43G,0.85N,0.18T,0.01R	0.96K, 0.01M, 0.04T, 0.01S	0.04T	0.01	.	0.23E, 0.01G,0.01N	5.49V,0.11T	2.32
1b	9.34G,4.46T,3.2N,0.04R	.	0.01T	.	0.03	0.67E, 0.03Q,0.01V	66.1V,0.15T	96.4
1c	80N	.	.	.	.	.	80V	.
1d	6.67T	.	.	.	.	.	100V	100
1e	73.3N,20.0T	.	.	.	.	.	93.3V	.
1g	20N	.	.	.	.	.	100V	.
1h	16.7T	16.67K	.	.	.	.	100V	100
1i	.	.	.	.	.	.	100V	100
1j	100N	.	.	.	.	.	100V	.
1k	100T	.	.	.	.	.	100V	.
1l	22.2T,	.	.	.	.	.	.	.
1l	11.1N	.	.	.	.	.	88.9V	.
1m	50T	.	.	.	.	.	.	.
1n	.	.	.	.	.	.	.	50
2a	1.89R	.	.	.	.	.	1.89V	1.89
2b	100R	.	.	.	.	.	1.80V	.
2c	100R	.	.	.	.	.	.	.
2d	100R	.	.	.	.	.	.	.
2e	100R	.	.	.	.	.	.	.
2f	100R	.	.	.	.	.	.	.
2i	100R	.	.	.	.	.	.	.
2j	100R	.	.	.	.	.	.	.
2k	75R	.	.	.	.	.	25V	25
2l	100R	.	.	.	.	.	100V	.
2m	100R	.	.	.	.	.	.	.
2q	100R	.	.	.	.	.	.	.
2r	100T	.	.	.	.	.	.	.
2t	100R	.	.	.	.	.	.	.
2u	.	.	.	.	.	.	.	.
3a	0.37T	0.25K	0.12G	.	5.59T	98.9Q,0.50R,0.13H/K	4.41V	0.13
3b	0.73T	5.07I, 4.35M	.	.	.	100Q	.	.
3d	.	.	.	.	.	100Q	.	.
3e	.	.	.	.	.	100Q	.	.

(Continued)

Table 1 (Continued).

Sub-type	S122 DGNRT	R155 CGIKLNQSTW	A156 GHKLMSTV	V158A	A166T	D168 Anyone	I170 TV	L175M
3g	.	.	.	.	.	100Q	.	.
3h	.	.	.	.	.	100Q	.	.
3i	.	.	.	.	.	100Q	100V	.
3k	.	.	.	.	.	100Q	.	.
4a	96.7T	.	.	.	.	.	90.6V	.
4b	50T	.	.	.	.	.	100V	.
4c	100T	.	.	.	.	.	100V	.
4d	95.7T	.	.	.	1.75	.	98V	.
4f	100T	.	.	.	.	.	100V	.
4g	100T	.	.	.	.	.	100V	.
4k	100T	.	.	.	.	.	100V	.
4l	100T	.	.	.	.	.	100V	.
4m	.	.	.	.	.	.	75V	.
4n	100T	.	.	.	.	.	100V	.
4o	100T	.	.	.	.	.	100V	.
4p	100T	.	.	.	.	.	100V	.
4q	100N	.	.	.	.	.	100V	.
4r	100T	.	.	.	.	.	100V	.
4s	100N	.	.	.	.	100T	100V	.
4t	100T	.	.	.	.	.	100V	.
4v	75N	.	.	.	.	.	100V	.
4w	100T	.	.	.	.	.	100V	.
5a	73.9T	.	.	.	.	.	8.7V	.
6a	76.3N,0.49D/G	.	.	.	0.49	43.5E	0.24V	100
6b	100T	.	.	.	.	1.71E	.	100
6c	.	.	.	.	.	.	100V	100
6d	100T	.	.	.	.	.	100V	100
6e	80T	.	.	.	.	.	100V	100
6f	100T	.	.	.	.	.	100V	100
6g	100N	.	.	.	.	50E	100V	100
6h	100N	.	.	.	.	.	80V/20A	100
6i	.	.	.	.	.	.	100V	100
6j	100N	.	.	.	.	.	100V	100

(Continued)

Table 1 (Continued).

Sub-type	S122 DGNRT	R155 CGIKLNQSTW	A156 GHKLMSTV	V158A	A166T	D168 Anyone	I170 TV	L175M
6k	I00T	.	.	.	.	.	100V	100
6l	25N,25T	.	12.5V	.	.	.	100V	100
6m	I00T	.	.	.	.	.	.	100
6n	I00N	.	.	.	.	.	100V	100
6o	I00T	.	.	.	.	.	100V	100
6p	I00T	.	.	.	.	.	100V	100
6q	I00T	.	.	.	.	.	100V	100
6r	I00T	.	.	.	.	.	100V	100
6s	66.7T	.	.	.	.	.	100V	100
6t	I00T	.	.	.	.	.	100V	100
6u	I00T	.	.	.	.	.	100V	100
6v	I00T	.	.	.	.	.	100V	100
6w	.	.	.	.	.	.	100V	100
6xa	I00T	.	.	.	.	.	100V	100
6xb	I00T	.	.	.	.	.	100V	100
6xc	I00T	.	.	.	.	.	100V	100
6xd	66.7N	.	.	.	.	.	50V	100
6xe	I00T	.	.	.	.	.	.	100
6xf	I00T	.	.	.	.	.	100V	100
7a	I00G	.	.	.	.	100Q	100V	100
7b	.	.	.	.	.	100Q	.	.

**Notes:** Data are presented as %. The dot denotes 0%. \*Not all the positions were analyzed using the same number of sequences. The first figure is the lowest number, and the second figure is the largest number. n.a.: not applicable because of different natural amino acid sequences in the respective HCV genotype/subtype (NS3 V170 and M175 are the dominant amino acids in GT1b).

some inhibitors for treating the corresponding subtypes. V36L, associated with resistance to asunaprevir, paritaprevir, and faldaprevir, was uncommon in GT1a (1.50%) and 1b (0.96%) but more frequent (13.33% to 100%) in five GT1 subtypes including 1d, 1e, 1g, 1i, and 1l. This RAS was also found in almost all GT2, 3, 4, 5, and 7 sequences, as well in several GT6 subtypes. Another asunaprevir/paritaprevir/faldaprevir RAS, V36M, was only observed in GT1a (0.48%) and 1b (0.03%). T54S was infrequent in GT1a (3.02%) and 1b (2.01%). The frequency of V170A was extremely low (<0.1%) in GT1a or GT1b but significantly varied among other subtypes with respect to frequency. Lastly, three RASs (Q41R, F43L/S, Y56H) were only found in GT1a or GT1b and at an extremely low prevalence. (<0.1%)

### Prevalence of naturally occurring NS5A RASs in 86 HCV subtypes

The prevalence of naturally occurring NS5A RASs in different HCV subtypes is shown in Table 2. Similar to NS3, most RASs were absent or have very low frequencies (<0.5%) (Figure S1B). RAS Y93H was associated with reduced NS5A-targeted DAA efficacy, with or without L31M/V/I, in GT1b-infected patients.<sup>40</sup> Y93H appeared in sequences of subtypes GT1a (0.41%, 12/2928), 1b (4.25%, 80/1882), 1c (25%, 1/4), 1m (50%, 1/2), 3a (1.35%, 14/1114), 4a (3.33%, 1/30), 4b (50%, 1/2), 4g (33.33%, 1/3), 7a (100%, 2/2) and 7b (100%, 1/1). Other substitutions at this position, such as Y93C/F/N/S, were uncommon in GT1a, 1b, 2a, 3a, and 6a (0.03%-1.92%), but were prevalent in other subtypes, including GT1c, 1g, 1m, 4w, 6e, 6m, 6n, 6o, 6u, 6v, and 6xe (15.38%-100%). L31M, which confers resistance to daclatasvir/ombitasvir/ledipasvir, has been associated with reduced elbasvir/grazoprevir efficacy in patients with HCV-GT1a infection.<sup>17</sup> L31M was rare in GT1a (0.65%, 19/2928) and 1b (2.63%, 49/1865) sequences and absent in GT3a, 5a, and all GT6 subtypes except in one GT6a sequence. In contrast, this RAS was frequently detected ( $\geq 50\%$ ) in subtypes G1d, 1e, 1l, 1m, 3b, and a majority of GT2 and 4 subtypes. A30K, which is associated with daclatasvir resistance, was only detected in 2.25% of GT3a sequences but was found in nearly 100% of sequences from other GT3 subtypes. The most commonly observed RAS in GT1b was Q54H (26.76%, daclatasvir resistance). RASs L28M (daclatasvir/ombitasvir resistance) and R30Q

(daclatasvir resistance) were identified in 2.37% and 4.66% of GT1b sequences, respectively.

### Prevalence of naturally occurring NS5B NI-specific and NNI-specific RASs in 86 HCV subtypes

The prevalence of naturally occurring NI-specific NS5B RASs and NNI-specific RASs in different HCV subtypes is shown in Table 3. Except for a few RASs with high rates, others have very low rates (Figure S1C). A150V has recently been found to be associated with a reduced response to treatment with sofosbuvir and ribavirin, with or without pegylated interferon in GT3a infected patients.<sup>34</sup> A150V is highly prevalent in sequences of GT3a (31.5%, 103/327). L159F was found in 11.19% (297/2655) of GT1b sequences but in only 0.09% (2/2346) of GT1a sequences. S282T, the only known variant conferring sofosbuvir resistance in vitro, rarely appeared in GT1a (0.19%, 10/5182), 1b (0.15%, 11/7440), 2b (0.22%, 1/455), 3a (0.03%, 1/3003) and 4a (0.35%, 3/857).

All observed NNI-specific RASs are associated with dasabuvir. C316N was common in sequences of GT1b (43.09%, 3179/7377), GT4f (81.61%, 71/87), 4b (14.29%, 2/14), and 1e (10.17%, 6/59). C316H was observed in GT1b (1.19%, 88/7377) and 5–10% of several GT4 subtypes but was more prevalent in GT4r (60.32%, 76/126). The frequency of S556G was higher in GT1b than in GT1a (11.77% vs. 0.79%) and was found in 6h (85.71%, 6/7), 6e (5.26%, 1/19), and GT2, 3, 4, 5 and 7 subtypes (nearly 100%). However, this RAS was absent in other GT1 subtypes and GT6 subtypes, although S556N, a closely related variant, was harbored by GT4r (75%, 3/4). S556R was found in GT1a (0.34%) and in several GT6 subtypes (6a, 6e, 6n, 6o, 6p, 6q, 6s, 6t, 6u, 6xc, and 6xf).

### Geographical distribution of RASs

Country of origin information was available for approximately 70% of the analyzed sequences. We classified these sequences into Asia, Europe, North America, Central America, South America, Former USSR, Oceania, Africa, Caribbean, or Middle East clusters according to geographic region definitions in the Los Alamos HCV Database. The majority of RASs in most HCV subtypes were similarly distributed among different geographic regions worldwide. NS3 RASs with distinctly variable prevalence by geographic region including Q80K in GT1a, V36L in GT1a, S122G in GT1b and so on

Table 2 Prevalence of naturally occurring NS5A RASs in 86 HCV subtypes

Subtype	No. of seq <sup>a</sup>	K24 AEGNQ <sup>b</sup>	M28 AGIKSTV	F28CS	L28 AFIMSTV	Q30 DEGHKLNRSY	R30 CEGHKNQST	A30 GHKV
1a	2855, 2928	0.46R, 0.21E, 0.32Q	3.79V, 0.38T, 0.10I	n.a.	n.a.	1.30L, 0.79H, 0.44R	n.a.	n.a.
1b	1817, 1882	1.93K	n.a.	n.a.	0.11F, 2.37M, 0.11V	n.a.	4.66Q, 0.59K, 0.05H	n.a.
1c	4	.	50V	.	50M, 50V	.	100Q	.
1d	1	.	.	.	.	100R	.	.
1e	2	50R	.	.	100M	.	100Q	.
1g	2	50R	.	.	.	50.00R	50.00Q	.
1h	3	100Q	.	.	.	100R	.	.
1i	1	100Q	.	.	.	100R	.	.
1j	1	.	.	.	100M	.	100Q	.
1k	1	.	100A	.	100A	.	100Q	.
1l	3	66.67G	.	.	100M	33.33R	66.67Q	.
1m	2	.	.	.	100M	50S	50S, 50Q	.
1n	2	.	.	.	100M	.	100Q	.
2a	52	.	.	.	100F	100K	100K	100K
2b	145	.	.	.	4.83F	99.3K	99.3K	99.3K
2c	9	.	.	33.3C	66.67F	22.2R, 77.8K	77.8K	77.8K
2d	1	.	.	.	.	100K	100K	100K
2e	1	.	.	.	100F	100K	100K	100K
2f	2	50F	50S	50S	50F, 50S	100K	100K	100K
2i	4	.	.	.	100F	100K	100K	100K
2j	6	.	.	.	66.67F	100K	100K	100K
2k	4	25Q	.	.	25.00F	25R, 75K	75K	75K
2l	2	.	.	.	.	100K	100K	100K
2m	4	.	.	.	.	50R, 50K	50K	50K
2q	2	.	.	.	.	100K	100K	100K
2r	1	.	.	.	100F	100K	100K	100K
2t	1	.	.	.	.	100K	100K	100K
2u	1	.	.	.	100F	100K	100K	100K
3a	1112, 1114	1.08A, 0.09T	0.27V, 0.09T	.	0.09T, 99.2M	1.26L, 0.90T, 0.45S	0.90T, 0.45S	2.25K, 0.81V
3b	19	.	.	.	100M	5.26R, 84.2K	84.2K	84.2K

(Continued)

Table 2 (Continued).

Subtype	No.of seq <sup>a</sup>	K24 AEGNQR <sup>b</sup>	M28 AGIKSTV	F28CS	L28 AFIMSTV	Q30 DEGHIKLNIRSTY	R30 CEGHKNQST	A30 GHKV
3d	1	.	.	.	100M	100K	100K	100K
3e	1	.	.	.	100M	100K	100K	100K
3g	2	50T	.	.	100M	100K	100K	100K
3h	2	.	.	.	100M	.	.	.
3i	6	.	.	.	100M	16.67R,83.3K	83.3K	83.3K
3k	2	100G	.	.	50M	100K	100K	100K
.	.	.	.	.	.	.	.	.
4a	30	.	6.67V	.	10M,6.67V	86.67L,3.33R,3.33H,3.33S	3.33H,3.33S	3.33H
4b	2	.	.	.	.	50.00S	50.00S	.
4c	1	.	.	.	.	100R	.	.
4d	11	.	.	.	.	90.91R	.	.
4f	6	.	.	.	.	66.67R	33.33Q	.
4g	3	.	.	.	.	66.67L,33.33R	.	.
4k	3	.	.	.	.	100R	.	.
4l	3	.	.	.	.	100R	.	.
4m	4	.	.	.	.	100S	100S	.
4n	3	.	.	.	.	100R	.	.
4o	4	.	.	.	100M	100T	.	.
4p	1	.	.	.	.	100R	.	.
4q	1	.	.	.	.	100R	.	.
4r	7	.	42.86V,28.61	.	28.61,28.6M,42.7V	100R	.	.
4s	1	.	.	.	.	100R	.	.
4t	1	.	.	.	.	100R	.	.
4v	4	.	.	.	.	100R	.	.
4w	2	.	.	.	100M	100S	100S	.
.	.	.	.	.	.	.	.	.
5a	23	100Q	.	.	.	.	100Q	.
6a	116	89.7Q,6.03R	2.59V	.	23.3F,2.59V	100R	.	.
6b	2	.	100T	.	100T	100R	.	.
6c	2	.	100V	.	100V	50T	50T	.

(Continued)

Table 2 (Continued).

Subtype	No.of seq <sup>a</sup>	K24 AEGNQR <sup>b</sup>	M28 AGIKSTV	F28CS	L28 AFIMSTV	Q30 DEGHIKLNIRSTY	R30 CEGHKNQST	A30 GHKV
6d	1	100R	100V	.	100V	100T	100T	.
6e	13	15.38R	46.15V	.	53.9M,46.2V	100S	100S	.
6f	18	.	61.11T,38.89A	.	61.1T,38.9A	100S	100S	.
6g	2	.	.	.	100M	50.00S	50.00S	.
6h	5	.	100V	.	100V	.	.	.
6i	3	.	66.67V	.	66.67V	.	.	.
6j	4	.	100V	.	100V	.	.	.
6k	8	25R	100V	.	100V	.	.	.
6l	7	.	100V	.	100V	.	.	.
6m	4	.	100V	.	100V	100S	100S	.
6n	9	.	100V	.	100V	100S	100S	.
6o	4	.	.	.	.	.	.	.
6p	3	.	66.67V	.	33.3M,66.7V	100S	100S	.
6q	3	.	100V	.	100V	100S	100S	.
6r	3	.	33.33G,33.33T	.	33.33T	.	.	.
6s	3	33.33R	.	.	33.3M	100S	100S	.
6t	4	.	100V	.	100V	100S	100S	.
6u	2	.	100V	.	100V	100S	100S	.
6v	4	.	100V	.	100V	100S	100S	.
6w	3	.	100T	.	100T	.	.	.
6xa	3	.	100V	.	100V	100S	100S	.
6xb	2	.	100V	.	100V	.	.	.
6xc	1	.	100V	.	100V	.	.	.
6xd	3	.	.	.	66.67F	100R	100R	.
6xe	2	.	100V	.	100V	100S	100S	.
6xf	2	50R	100V	.	100V	.	.	50V
7a	2	.	.	.	.	100S	100S	.
7b	1	.	.	.	.	100S	100S	.

(Continued)

Table 2 (Continued).

Subtype	L31 FIMPVW	P32 ALQRS	Q54 H	H58 DLN <sup>c</sup>	E62 DL	A92KPT <sup>d</sup>	Y93 CFILNRSTW	Y93 H
1a	0.65M	0.03L,0.07S	96.52	0.10D,0.10N	1.4D	0.51P	0.24C,0.17N, 0.07F, 0.03S	0.41
1b	2.63M,0.27I,0.05F	0.05S	26.76	3.43S,0.8T,0.48L,0.48A,0.05R	0.05D,0.21L	1.28T	0.05C, 0.05F, 0.05S	4.25
1c	.	.	75.00	.	50D	.	25N	25.00
1d	100M	.	.	.	.	100T	.	.
1e	50M	.	50.00	.	.	.	100F	.
1g	.	.	.	.	.	.	.	.
1h	.	.	100	.	.	.	.	.
1i	.	.	.	.	.	.	.	.
1j	.	.	.	.	.	.	.	.
1k	.	.	.	.	.	.	.	.
1l	100M	.	33.33	.	.	.	.	.
1m	50M	.	.	.	50D	.	50.00C	50.00
1n	.	.	.	.	100D	.	1.92F	.
2a	82.7M	.	.	.	.	0.69A,0.69S	.	.
2b	64.8M	.	.	.	.	.	.	.
2c	11.1M	.	.	.	.	.	.	.
2d	.	.	.	.	.	.	.	.
2e	100M	.	.	.	.	100S	.	.
2f	100M	.	.	.	.	50S	.	.
2i	100M	.	.	.	.	.	.	.
2j	100M	.	.	.	.	.	.	.
2k	75M	.	25.00	.	.	.	.	.
2l	.	.	.	.	50L	25A	.	.
2m	100M	.	.	.	.	100S	.	.
2q	50M	.	.	.	.	100S	.	.
2r	100M	.	.	.	.	.	.	.
2t	.	.	.	.	.	.	.	.
2u	100M	.	.	.	.	.	.	.
3a	0.18P	.	.	0.09L	3.32L	.	0.36C, 0.09F	1.35
3b	84.2M,5.26V	.	.	.	36.8D	.	.	.

(Continued)

Table 2 (Continued).

Subtype	L31 FIMPVW	P32 ALQRS	Q54 H	H58 DLN <sup>c</sup>	E62 DL	A92KPT <sup>d</sup>	Y93 CFILNRSTW	Y93 H
3d	100M	.	.	.	.	.	.	.
3e	.	.	.	.	.	.	.	.
3g	50M,50V	.	.	.	.	.	.	.
3h	.	.	.	.	.	.	.	.
3i	.	.	.	.	.	.	.	.
3k	100M	.	.	.	100L	.	.	.
4a	.	.	.	.	.	.	.	.
4a	3.33V	.	100	.	10D	.	.	3.33
4b	.	.	100	.	50D	50P	50T	50.00
4c	.	.	100	.	.	.	.	.
4d	.	.	100	.	.	.	.	.
4f	.	.	100	.	.	.	.	.
4g	.	.	100	.	.	.	.	.
4g	.	.	100	.	.	.	33.3R	33.33
4k	66.7L	.	100	.	.	.	.	.
4l	.	.	100	.	.	.	.	.
4m	.	.	100	.	.	.	.	.
4n	33.3L	.	100	.	.	.	.	.
4o	.	.	100	.	25D	.	.	.
4p	.	.	100	.	.	.	.	.
4q	.	.	100	.	.	.	.	.
4r	85.7L	.	100	.	.	.	.	.
4s	100L	.	100	.	.	.	.	.
4t	.	.	100	.	.	.	.	.
4v	.	.	100	.	.	.	.	.
4w	.	.	100	.	.	.	100S	.
5a	L31FIMPVW	.	.	.	.	.	.	.
6a	0.86M	.	98.28	.	.	.	0.86I, 0.86S	.
6b	.	.	100	100S	1.72L	.	.	.
6c	.	.	100	100G	.	100P	.	.
6d	.	.	.	100S	.	.	100I	.
6e	.	.	.	7.69H	.	.	15.38S	.

(Continued)

Table 2 (Continued).

Subtype	L31 FIMPVW	P32 ALQRS	Q54 H	H58 DLN <sup>c</sup>	E62 DL	A92KPT <sup>d</sup>	Y93 CFILNRSTW	Y93 H
6f	.	.	94.44	16.7S,5.56L	.	.	.	.
6g	.	.	.	.	.	.	.	.
6h	.	.	100	20S	.	.	.	.
6i	.	.	100	.	66.7D	.	.	.
6j	.	.	75.00	50A	50D	.	.	.
6k	.	.	25.00	.	87.5D	.	.	.
6l	.	.	.	.	100D	.	.	.
6m	.	.	100	.	.	.	100S	.
6n	.	.	100	.	.	.	100S	.
6o	.	.	.	100A	.	.	50S	.
6p	.	.	100	.	.	.	.	.
6q	.	.	100	.	.	.	.	.
6r	.	.	.	33.3S	.	.	.	.
6s	.	.	100	.	.	.	.	.
6t	.	.	.	100G	.	.	100S	.
6u	.	.	.	.	.	.	100S	.
6v	.	.	.	.	.	.	.	.
6w	.	.	100	.	66.7D	.	.	.
6xa	.	.	100	.	.	.	.	.
6xb	.	.	.	.	100D	.	.	.
6xc	.	.	.	.	.	.	.	.
6xd	.	.	100	33.3A	.	.	.	.
6xe	.	.	100	.	.	.	100S	.
6xf	.	.	.	.	.	.	.	.
7a	.	.	.	.	100L	.	.	100
7b	.	.	.	.	.	.	.	100

**Notes:** Data are presented as %. The dot denotes 0%. <sup>a</sup>Not all the positions were analyzed using the same number of sequences. The first figure is the lowest number, and the second figure is the largest number; n.a. not applicable because of different natural amino acid sequences in the respective HCV genotype/subtype (NS5A K24, M28, Q30, and H58 are the dominant amino acids in GT1a; F28 is the dominant amino acid in subtype 2a and L28 in subtype 2b; A30 is the dominant amino acid in GT3; T93 is the dominant amino acid in GT6). <sup>b</sup>For GT1b, Q24K was screened; for GT3 and GT2 except GT2a, S24FHT were screened. <sup>c</sup>For GT1b, P58A/D/G/L/R/S/T was screened; for GT6, T58A/D/G/H/L/N/S were screened. <sup>d</sup>For GT2, C92A/K/N/R/S/T was screened; for GT3, E92K were screened. No sequences harbored S38F. K26E was found in 0.11% of 1a, and 0.27% of 3a sequences.

**Table 3** Prevalence of naturally occurring NS5B RASs in 86 HCV subtypes

Sub type	No.of seq <sup>a</sup>	NS5B NI RAS position							
		A150 V	L159 F	K206 E	E237G	S282 TGR	M289 IL	L320 F	V321AI
1a	1433, 5412	.	0.09	0.12	1.54	0.19T,0.02G,0.02R	0.10L	0.02	0.23I,0.02A
1b	2090, 7462	0.08V	11.2	0.03	0.06	0.15T,0.26R,0.03G	0.01I	0.03	1.83I,0.01A
1c	3, 27	.	.	.	.	.	.	.	.
1d	1, 27	.	.	.	.	.	.	.	.
1e	2, 59	.	.	.	.	.	.	.	.
1g	2, 41	.	.	.	.	.	.	.	2.7I
1h	3, 30	.	.	.	.	.	.	.	.
1i	1, 6	.	.	.	.	.	.	.	.
1j	1, 4	.	.	.	.	.	.	.	.
1k	1, 8	.	.	.	.	.	.	.	100I
1l	3, 40	.	.	.	.	.	.	.	2.5I
1m	2, 5	.	.	.	.	.	.	.	.
1n	2, 2	.	.	.	.	.	.	.	100I
2a	28, 742	13.8	.	.	.	.	1.49I, 0.54L	0.14	.
2b	97, 460	1.03	.	.	3.02	0.22T	7.73I	.	0.44I
2c	13, 286	.	.	.	.	.	0.35I	.	0.78I
2d	1, 9	.	.	.	.	.	.	.	.
2e	1, 25	.	.	.	.	.	100L	.	.
2f	2, 14	.	.	.	.	.	.	.	.
2i	4, 84	.	.	.	.	.	.	.	.
2j	6, 89	.	.	.	.	.	1.19I, 2.38L	.	.
2k	9, 72	.	.	16.7	4.76	.	1.12I	.	.
2l	2, 20	.	.	.	.	.	1.39I	.	3.17I
2m	3, 21	.	.	.	.	.	5.00I, 90.0L	.	.
2q	2, 5	.	.	.	.	.	.	.	.
2r	1, 13	100	.	.	.	.	20.00I	.	46.2I
2t	1, 1	.	.	.	.	.	.	.	.
2u	1, 1	.	.	.	.	.	.	.	.
3a	90, 3155	31.5	.	7.38	0.45	0.2R,0.03T	0.07L	0.03	0.13I

(Continued)

Table 3 (Continued).

Sub type	No.of seq <sup>a</sup>	NS5B NI RAS position							
		AI50 V	LI59 F	K206 E	E237G	S282 TGR	M289 IL	L320 F	V321AI
3b	20, 672	2.63	.	7.92	0.67	0.15G	.	.	.
3d	1, 3	.	.	100	.	.	.	.	.
3e	1, 4	.	.	.	.	.	.	.	.
3g	2, 8	.	.	.	.	.	.	.	.
3h	2, 12	.	.	.	.	.	100L	.	.
3i	5, 20	.	.	33.3	.	.	.	.	.
3k	2, 57	.	.	55.6	.	.	.	.	.
4a	42, 857	.	.	.	10.05	0.35T,0.12R	0.95L	0.12	0.12I
4b	2, 14	.	.	.	.	.	7.14L	.	7.14I
4c	1, 59	.	.	.	.	1.69G	.	.	3.77I
4d	25, 672	.	.	.	0.95	0.18R	0.18I, 0.18L	.	.
4f	5, 87	.	.	.	2.38	.	.	.	.
4g	3, 16	.	.	.	.	.	.	.	6.25I
4k	3, 127	.	.	.	.	1.57G	0.79L	.	7.14I
4l	5, 31	.	.	.	9.68	.	7.69L	.	.
4m	4, 29	.	.	25	.	.	.	.	.
4n	2, 31	.	.	.	3.23	.	.	.	.
4o	4, 44	.	.	.	.	.	2.38I	.	.
4p	1, 16	.	.	.	.	.	.	.	.
4q	1, 15	.	.	.	.	.	26.7L	.	.
4r	3, 126	.	.	.	1.15	.	.	.	60.3I
4s	1, 3	.	.	.	.	.	.	.	.
4t	1, 22	.	.	.	.	.	.	.	.
4v	2, 6	.	.	.	66.67	.	16.7L	.	.
4w	2, 2	.	.	.	.	.	.	.	.
5a	37, 419	.	.	.	.	.	.	0.25	.
6a	118, 1290	.	.	.	.	0.08R	1.19I	.	.
6b	2, 9	.	.	.	.	.	1.16L	.	.
6c	2, 12	.	.	.	.	.	77.8L	.	.
6d	1, 13	.	.	.	.	.	100L	.	.

(Continued)

Table 3 (Continued).

Sub type	No.of seq <sup>a</sup>	NS5B NI RAS position						
		A150 V	L159 F	K206 E	E237G	S282 TGR	M289 IL	L320 F
6e	16, 139	.	.	.	.	.	98.6L	.
6f	5, 121	.	.	.	.	.	98.4L	0.871
6g	2, 5	.	.	.	.	.	.	.
6h	5, 42	.	.	.	.	.	.	.
6i	4, 38	.	.	.	.	.	.	.
6j	4, 16	.	.	.	.	.	50.0L	.
6k	8, 31	.	.	.	.	.	100L	.
6l	7, 42	.	.	14.3	.	.	100L	.
6m	4, 21	.	.	87.5	.	.	.	.
6n	8, 196	.	.	6.45	.	.	94.9L	0.541
6o	4, 13	.	.	.	.	.	100L	.
6p	2, 15	.	.	.	.	.	6.671, 93.3L	.
6q	3, 18	.	.	.	.	.	100L	16.71
6r	3, 11	.	.	.	.	.	100L	.
6s	3, 5	.	.	.	100	.	100L	.
6t	4, 4	.	.	.	.	.	100L	.
6u	2, 43	.	.	.	.	.	100L	.
6v	4, 6	.	.	.	.	.	4.65L	.
6w	3, 4	.	.	.	.	.	.	.
6xa	3, 4	.	.	.	.	.	100 L	.
6xb	2, 2	.	.	.	.	.	.	.
6xc	1, 1	.	.	.	.	.	100L	.
6xd	3, 3	.	.	.	.	.	100L	.
6xe	2, 2	.	.	50	.	.	33.3L	.
6xf	2, 4	.	.	.	.	.	100L	.
7a	2, 2	.	.	.	.	.	100L	.
7b	1, 2	.	.	.	.	.	.	.

(Continued)

Table 3 (Continued).

Sub type	NS5B NNI RAS position											
	C316 NYHF	S368T	N411S	M414 TIV	C445 F	E446 KQ	Y448 CH	A553 ITV	G554 SD	S556 GNR	G558R	D559GN
1a	0.02N, 0.09Y	.	.	0.11T	.	0.11Q, 0.04K	0.07H, 0.04C	0.06V	.	0.79G,0.34R, 0.11N	0.42	.
1b	43.09N, 0.09Y,1.19H	0.03	.	0.14T, 0.32I,0.03V	0.67	98.46Q	0.26H, 0.03C	.	0.09D	11.77G,0.83N	0.09	0.05N
1c	.	.	.	.	.	.	.	.	.	.	.	.
1d	.	.	.	.	.	100Q	.	.	.	.	.	.
1e	10.17N	.	.	.	.	.	.	.	.	.	.	.
1g	5.26Y, 2.63H	.	.	.	.	20Q	.	.	.	.	.	.
1h	.	.	.	.	100	100Q	.	.	.	.	.	.
1i	.	.	.	.	.	.	.	.	.	.	.	.
1j	.	.	.	.	.	.	.	.	.	.	.	.
1k	.	.	.	.	.	.	100H	.	.	.	.	.
1l	2.50H	.	.	.	.	.	.	.	.	.	.	.
1m	.	.	.	.	.	.	.	.	.	.	.	.
1n	.	.	.	.	.	.	.	.	.	.	.	.
2a	0.14Y	.	.	.	100	.	.	100V	.	100G	.	.
2b	.	.	.	.	100	.	.	95.37V	.	100G	.	.
2c	.	.	.	.	100	.	.	87.5V, 6.25I	100S	100G	.	.
2d	.	.	.	.	100	.	.	100V	.	100G	.	.
2e	.	.	.	.	100	.	.	87.5V	.	100G	.	.
2f	.	.	.	.	100	.	.	75V	.	100G	.	.
								25I				
2i	.	.	.	.	100	.	.	100	100S	100G	.	.
2j	.	.	.	.	100	.	.	50V, 33.3I, 16.7T	.	100G	.	.
2k	3.12H	.	.	.	90.9	9.09Q	.	88.89V	.	88.9G	.	.
2l	.	.	.	.	100	.	.	100V	.	100G	.	.
2m	.	.	.	.	100	.	.	100V	100S	100G	.	.
2q	.	.	.	.	100	.	.	100V	.	100G	.	.
2r	7.69N, 7.69Y	.	.	.	100	.	.	100V	.	100G	.	.
2t	.	.	.	.	100	.	.	100V	.	.	.	.
2u	.	.	.	.	100	.	.	100V	.	.	.	.
3a	0.03Y	.	0.34	.	99.7	0.12Q	.	100V	1.04S	97.8G	.	1.11N

(Continued)

(Continued)

Table 3 (Continued).

Sub type	NS5B NNI RAS position										G558R	D559GN
	C316 NYHF	S368T	N411S	M414 TIV	C445 F	E446 KQ	Y448 CH	A553 ITV	G554 SD	S556 GNR		
3b	.	.	.	.	100	0.99Q	0.33H	100V	.	100G	.	
3d	.	.	.	.	100	100Q	.	100V	.	100G	.	
3e	.	.	.	.	100	.	.	100V	.	100G	.	
3g	.	.	.	.	100	.	.	100V	.	100G	.	
3h	.	.	.	.	100	.	.	100V	.	100G	.	
3i	.	.	.	.	100	.	.	100V	.	100G	.	
3k	.	.	.	.	100	.	.	100V	.	100G	.	
4a	0.48N	.	.	91.4V,7.76I	100	.	.	100V	.	100G	.	
4b	14.29N, 7.14H	.	.	50V	100	.	.	100V	.	100G	.	
4c	5.66Y, 3.77H	.	.	100I	100	.	.	100V	.	100G	.	
4d	0.16Y	.	.	2.80T, 96.8I	100	.	.	100V	.	100G	.	
4f	81.61N	.	.	83.3V,16.7I	100	.	.	100V	.	100G	.	
4g	6.25H	.	.	.	100	.	.	100V	.	100G	.	
4k	0.79Y, 4.76H	.	.	.	100	.	.	100V	.	100G	.	
4l	.	.	.	.	100	.	.	100V	.	100G	.	
4m	.	.	.	.	100	.	.	100V	.	100G	.	
4n	4.35Y	.	.	.	100	.	.	100V	.	100G	.	
4o	.	.	.	.	100	.	.	100V	.	100G	.	
4p	.	.	.	.	100	.	.	100V	.	100G	.	
4q	.	.	.	.	100	.	.	100V	.	100G	.	
4r	60.3H,0.79N	.	.	9.09I	100	.	.	100V	.	75N	.	
4s	.	.	.	.	100	.	.	100V	.	100G	.	
4t	.	.	.	.	100	.	.	100V	.	100G	.	
4v	.	.	.	.	100	.	.	100V	.	100G	.	
4w	.	.	.	.	100	.	.	100V	.	100G	.	
5a	.	.	.	.	98.1	.	.	100V	5.41S	97.3G	.	
6a	.	.	.	.	100	.	0.41H	.	.	0.84R	.	
6b	.	.	.	.	100	.	.	.	.	.	.	
6c	.	.	.	.	100	.	.	.	.	.	.	
6d	.	.	.	.	100	.	.	.	.	.	.	


(Continued)

(Continued)

Table 3 (Continued).

Sub type	NS5B NNI RAS position											
	C316 NYHF	S368T	N411S	M414 TIV	C445 F	E446 KQ	Y448 CH	A553 ITV	G554 SD	S556 GNR	G558R	D559GN
6e	0.72Y	2.33	.	.	98.2	.	.	.	.	5.26G,94.7R	.	.
6f	.	.	.	.	100	.	.	.	.	.	.	.
6g	.	.	.	.	100	.	.	.	.	.	.	.
6h	.	.	.	.	100	.	.	.	.	85.71G	.	.
6i	.	.	11.1	.	100	.	.	.	.	.	.	.
6j	.	.	.	.	100	.	.	.	.	.	.	.
6k	.	.	.	.	100	.	.	.	.	.	.	.
6l	.	.	.	.	100	.	.	.	.	.	.	.
6m	.	.	.	.	100	.	.	.	.	.	.	10.0G
6n	.	.	.	1.16V	100	.	1.16H	.	.	12.5R	.	.
6o	.	.	.	.	100	.	.	25V	.	75R	.	.
6p	.	.	.	.	100	.	.	50V	.	100R	.	.
6q	.	.	.	.	100	.	.	.	.	100R	.	.
6r	.	.	.	.	100	.	.	.	.	.	.	.
6s	.	.	.	.	100	.	.	100V	.	100R	.	.
6t	.	.	.	.	100	.	.	.	.	25R	.	.
6u	.	.	.	.	100	.	.	.	.	100R	.	.
6v	.	.	.	.	100	.	.	.	.	.	.	.
6w	.	.	.	.	100	.	.	.	.	.	.	.
6xa	.	.	.	.	100	.	.	.	.	.	.	.
6xb	.	.	.	.	100	.	.	.	.	.	.	.
6xc	.	.	.	.	100	.	.	.	.	100R	.	33.3G
6xd	.	.	.	.	100	.	.	.	.	.	.	.
6xe	.	.	.	.	100	.	.	.	.	.	.	.
6xf	.	.	.	.	100	.	.	.	.	100R	.	.
7a	.	.	.	.	100	.	.	100V	.	100G	.	.
7b	.	.	.	.	100	.	.	.	100S	100G	.	.

Notes: Data are presented as %. The dot denotes 0%. C451S were detected in 1.05% of 1b sequences, G188D in 0.82% of 3a, N224I in 3.06% of 3a and in 3.45% of 6k, A395G in 0.75% of 4a, and Y561H in 0.10% of 1b. L314H, N444K, S565F were not found. <sup>a</sup>Not all the positions were analyzed using the same number of sequences. The first figure is the lowest number, and the second figure is the largest number.




**Figure 1** The global and regional frequency of naturally occurring NS3 RASs that showed unequal distribution by geographic regions. In each plot, except for the first bar representing the global prevalence, geographic regions were arranged in descending order according to the frequency of RASs. Sequences were clustered into Asia, Europe, North America, Central America, South America, Former USSR, Oceania, Africa, Caribbean or Middle East. In each plot, regions with <10 sequences were not shown. Region definition was according to the Los Alamos HCV Database. "A" in North A, South A and Central A denotes America.

(Figure 1,  $P < 0.05$ ). Q80K in GT1a was mostly prevalent in North America (54.49%, 679/1246), followed by Europe (22.66%, 246/1090), Asia (6.98%, 3/43), Oceania (6.62%, 9/136), and South America (1.03%, 4/390). NS5A RASs (L28M, R30Q, Q54H, and Y93H in GT1b, L31M in GT2b, and E62L in GT3a) varied significantly in geographic prevalence (Figure 2, all  $P$ -values  $< 0.05$ ). L28M, R30Q, and Y93H in GT1b showed the highest prevalence in Asia. NS5B RASs exhibited distinct global distribution patterns are present in Figure 3. C316N/H was found mostly in Asia (73.20%, 1923/2627), followed by in the Former USSR (63.77%, 213/334), Europe (31.82%, 415/1304), North America (22.81%, 52/228), South America (21.39%, 182/851), Oceania (10.64%, 5/47), the Middle East (21.82%, 24/110), Africa (4.49%, 7/156), Central America (0%, 0/10), and the Caribbean (0%, 0/12). In

contrast, Asia had the lowest prevalence of L159F in GT1b (0.62%, 2/322), while S556G in GT1b commonly appeared in Oceania (26.92%, 7/26) but infrequently in North America (4.49%, 8/178). A150V in GT3a was most prevalent in Asia (44.09%), followed by Europe (31.19%), Oceania (24.29%), and North America (19.05%).

## Naturally occurring combined RASs

The associations of RASs within and between the HCV NS3, NS5A, and NS5B genes were investigated using a hypergeometric test to detect significantly more or less frequent RAS co-occurrences. This analysis identified pairs of variants that may result in improved or reduced fitness, and RASs were defined as co-occurring or mutually exclusive based on their observed frequencies. Subtypes GT1a and 1b were separately analyzed. For




**Figure 2** NSSA RASs rate with significantly different frequencies among different geographic regions. In each plot, the first bar represents the global prevalence and geographic regions were arranged in descending order according to the frequency of RASs. Sequences were clustered into Asia, Europe, North America, Central America, South America, Former USSR, Oceania, Africa, Caribbean or Middle East. In each plot, only regions with at least 10 sequences were shown. Region definition was according to the Los Alamos HCV Database. "A" in North A, South A and Central A denotes America.

each pair of RASs, only overlapping sequences were used.

Dozens of RAS pairs were identified. In GT1a, RAS combinations within NS3 is shown in Figure 4A. Q80K has three partners (R155K, D168E, and T54S), but the frequencies of all their combinations was significantly lower than expected. Q80K and R155K were respectively observed in 31.87% (2275/7137) and 0.96% (69/7137) of GT1a sequences, but the pair was only found in 0.056% (4/7137) of sequences compared with the expected level (0.308%). Thus, these RASs were considered a mutually exclusive pair. All of these RASs, except Q80K, showed significantly higher co-occurrences with other RASs than expected. For example, R155K tends to be present with V36M, D168G, and T54S. Co-occurring pairs in NS5A included L31M+Y93C and Q30H+Y93H (Figure 4B), and

those in NS5B included NI-L159F+NNI-S556G and NNI-M414T+NNI-S556G (Figure 4C). We also identified some co-occurring RASs pairs among NS3, NS5A, and NS5B, including NS3-Q80K+NA5A-M28T/V, NS3-T54S+NS5A-Q30H/L and NS3-V36M+NS5B-A553V and so on (Figure 4D). Two RASs from different regions co-occurred rarely in this study (one or two of the 734 sequences). This means that each of these RASs occurred rarely, but they tend to be co-occurred.

For GT1b, co-occurring pairs in NS3, NS5A, and NS5B were shown in Figure 4E, F, and G respectively. NS3 RAS pairs included T54S+Q80L, Y56F+S122T and so on. NS5A pairs included Y93H+Q54H and L28M+R30Q. Within NS5B, similar to GT1a, pairs NI-L159F+NNI-S556G and NNI-M414I/T+NNI-S556G were identified. Other pairs included C316H+V321I.



**Figure 3** NS5B RASs rate with significantly different frequencies among different geographic regions. In each plot, the first bar represents the global prevalence and geographic regions were arranged in descending order according to the frequency of RASs. Sequences were clustered into Asia, Europe, North America, Central America, South America, Former USSR, Oceania, Africa, Caribbean or Middle East. In each plot, only regions with at least 10 sequences were shown. Region definition was according to the Los Alamos HCV Database. "A" in North A, South A and Central A denotes America.


95.4% of sequences with 316H have 321I. Co-occurring pairs between NS3, NS5A, and NS5B, included NS5A-L28M+NS5B-C316N, NS5A-R30Q+NS5B-C316N, and NS3-V36L+NS5B-S556N (Figure 4H).

## Discussion

This study investigated naturally occurring RASs among all 86 confirmed HCV subtypes using nucleotide sequences from multiple public databases. We analyzed the frequency and distribution of RASs based on HCV subtype and global geographic regions. In addition, co-occurring RAS and mutually exclusive RAS pairs were identified in subtypes GT1a and 1b within or between the NS3, NS5A, and NS5B genes.

The frequency of Q80K in NS3 varied by both HCV subtype and geographic regions. This RAS was detected in

nearly one-third of HCV GT1a sequences and was particularly prevalent in North America, which corroborates findings from previous studies. The NS3 R155K and D168E substitutions, which confer resistance to simeprevir and cross-resistance to other NS3/4A protease inhibitors, appeared in 0.96% and 0.23% of HCV GT1a sequences, respectively. Frequencies of Q80K+R155K and Q80K+D168E were lower than expected, and the pairs appeared to be mutually exclusive. However, these observations contrast with those from another study in which 83% (29/35) of patients infected with HCV GT1a harboring Q80K who experienced virologic failure with simeprevir plus Peg-IFN $\alpha$ /RBV developed virus with a treatment-emergent R155K.<sup>41</sup> R155 enables protein conformation favorable for interactions with the quinoline moiety of simeprevir (TMC435), and the salt bridge network



Y93H was most prevalent in GT1b (dominant in Asia), and present in 1.35% GT3a and the two 7a and one 7b sequences. Its distribution may be associated with polymorphism of some immune genes. Nguyen et al suggested that the frequency of Y93H in patients who were *IFNL3* rs12979860 CC major homozygotes (30%, 3/10) was higher than in the non-CC group in Ireland (11.1%, 4/36),<sup>43</sup> and Asian patients also had a high frequency of *IFNL3* rs12979860 CC (approximately 90%).<sup>44</sup> This association may explain the prevalence of Y93H in Asia. Y93H variants reduce viral sensitivity to ledipasvir in the

The NI-specific RAS S282T, the only RAS to confer *in vitro* resistance to sofosbuvir, was detected in 27 sequences from GT1a, GT1b, GT2b, GT2h, GT3a, and GT4a. Although this RAS was widely distributed geographically, the most recent notation of this RAS in the searched databases was from 2008. This finding suggests S282T may be deleterious to HCV fitness and could explain why S282T has not been recently identified in samples from clinical trials and has only been found in a few patients with viral relapse in recent years.<sup>49–52</sup> The first case involving the S282T variant was reported when

viral breakthrough occurred at week 12 in a patient infected with genotype GT3a.<sup>49</sup>

L159F is not associated with reduced sofosbuvir susceptibility, although this RAS was frequently detected with C316N. The high frequency of this double mutation was reported in untreated Brazilian patients infected with GT1b.<sup>53</sup> The combination of L159F with C316N was also frequently found in GT1b-infected patients who failed to respond to sofosbuvir/ribavirin or other sofosbuvir-based regimens.<sup>54</sup> Notably, we found a very high prevalence of C316N, but a very low occurrence of L159F, in Asia. As demonstrated in a study of Japanese patients, deep sequencing showed that 30.0% of patients with C316N also carried L159F, indicating that the variant is present but not easily detected due to low abundance.<sup>55</sup> S556G significantly co-occurred with C316N in GT1b sequences, which reflects results from a previous study showed this combination after treatment failure with three DAAs (paritaprevir, ombitasvir, and dasabuvir) in GT1b-infected patients.<sup>56</sup>

Two important points need to be addressed. The first one is whether the observed RASs are the result of natural HCV variation or of transmission from patients who selected RASs during DAA treatment is unclear. This information was not available in overwhelming studies. In clinical practice, it is difficult to determine the source of infection. The second one is about sequences with highly similarity. Although we have excluded all the clones from the same individuals and only kept one sequence from DAA naive patients with multiple visits, we cannot rule out the possibility that there may be some sequences originated from the same individual at different time points but are not specified in NCBI or related publications.

In conclusion, we obtained the knowledge about the geographic and subtype specific prevalence for an updated list of RASs. Our data may be of special relevance for those countries where highly effective antivirals might not be available. Considering the geographic and subtype specific RASs prevalence will help the clinicians to make optimal treatment choices. The RASs pairs both mutually exclusive and co-occurring would benefit anti-HCV drug development. In addition, given that the emergence of RASs is a growing issue in the setting of current treatment with DAAs, the results provide valuable data on the baseline prevalence, which can be used to monitor for increasing antiviral resistance in the future.

## Abbreviations

DAA, direct-acting antiviral; GT, genotype; HCV, hepatitis C virus; NI, nucleos(t)ide inhibitors; NNI, non-nucleoside inhibitors; RAS, resistance-associated substitution; SVR, sustained virologic response.

## Acknowledgments

We are grateful to Dr. Hongmei Mo for the suggestion. This work was supported by the Natural Science Foundation of China [grant number 81301415], Natural Science and Technology Major Project [grant number 2014ZX10002002] and Program for JLU Science and Technology Innovative Research Team [grant number 2017TD-08].

## Author contributions

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Lavanchy D. The global burden of hepatitis C. *Liver Int.* 2009;29 Suppl 1:74–81. doi:10.1111/j.1478-3231.2008.01934.x
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. *J Hepatol.* 2014;61(1 Suppl):S58–S68. doi:10.1016/j.jhep.2014.07.012
3. El-Serag HB. Hepatocellular carcinoma. *N Engl J Med.* 2011;365(12):1118–1127. doi:10.1056/NEJMra1001683
4. Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. *Proc Natl Acad Sci U S A.* 2013;110(10):3991–3996. doi:10.1073/pnas.1203110110
5. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science.* 1998;282(5386):103–107. doi:10.1126/science.282.5386.103
6. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology.* 2014;59(1):318–327. doi:10.1002/hep.26744
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA.* 2012;308(24):2584–2593. doi:10.1001/jama.2012.144878
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med.* 2004;140(5):346–355. doi:10.7326/0003-4819-140-5-200403020-00010
9. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med.* 2005;352(25):2609–2617. doi:10.1056/NEJMoa042608
10. Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. *PLoS One.* 2009;4(8):e6579. doi:10.1371/journal.pone.0006579

11. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. *Liver Int.* **2016**;36 Suppl 1:47–57. doi:10.1111/liv.13027
12. McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. *Antimicrob Agents Chemother.* **2009**;53(5):2129–2132. doi:10.1128/AAC.01598-08
13. Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. *PLoS One.* **2012**;7(7):e39652. doi:10.1371/journal.pone.0039652
14. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. *Hepatology.* **2011**;53(5):1742–1751. doi:10.1002/hep.24262
15. McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. *Hepatology.* **2013**;58(3):902–911. doi:10.1002/hep.26388
16. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. *J Hepatol.* **2013**;58(4):646–654. doi:10.1016/j.jhep.2012.11.012
17. Komatsu TE, Boyd S, Sherwat A, et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. *Gastroenterology.* **2017**;152(3):586–597. doi:10.1053/j.gastro.2016.10.017
18. Ji F, Wei B, Yeo YH, et al. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. *Aliment Pharmacol Ther.* **2018**;47(5):550–562. doi:10.1111/apt.14507
19. Panel AIGHG. Hepatitis C guidance: AASLD-IDS recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology.* **2015**;62(3):932–954. doi:10.1002/hep.27950
20. European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. *J Hepatol.* **2015**;63(1):199–236. doi:10.1016/j.jhep.2015.03.025
21. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naïve patients prior to treatment. *J Virol.* **2013**;87(3):1544–1553. doi:10.1128/JVI.02294-12
22. Paolucci S, Fiorina L, Mariani B, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. *Virol J.* **2013**;10:355. doi:10.1186/1743-422X-10-355
23. Costantino A, Spada E, Equestre M, et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. *Virol J.* **2015**;12:186. doi:10.1186/s12985-015-0414-1
24. Wang Y, Rao HY, Xie XW, et al. Direct-acting antiviral agents resistance-associated polymorphisms in chinese treatment-naïve patients infected with genotype 1b hepatitis C virus. *Chin Med J (Engl).* **2015**;128(19):2625–2631. doi:10.4103/0366-6999.166038
25. Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. *Infect Drug Resist.* **2017**;10:377–392. doi:10.2147/IDR.S146595
26. Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. *Sci Rep.* **2016**;6:20310. doi:10.1038/srep20310
27. Kliemann DA, Tovo CV, Da Veiga AB, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. *World J Gastroenterol.* **2016**;22(40):8910–8917. doi:10.3748/wjg.v22.i40.8910
28. Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, López-Labrador FX. Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. *Antimicrob Agents Chemother.* **2016**;60(4):2402–2416. doi:10.1128/AAC.02776-15
29. Welzel TM, Bhardwaj N, Hedskog C, et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. *J Hepatol.* **2017**;67(2):224–236. doi:10.1016/j.jhep.2017.03.014
30. Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. *Drug Resist Updat.* **2018**;37:17–39. doi:10.1016/j.drug.2018.01.004
31. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. *J Hepatol.* **2016**;64(2):486–504. doi:10.1016/j.jhep.2015.09.011
32. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. *Gastroenterology.* **2016**;151(1):70–86. doi:10.1053/j.gastro.2016.04.003
33. Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. *Antimicrob Agents Chemother.* **2018**;62(1):e01620–17.
34. Wing PAC, Jones M, Cheung M, et al. Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir. *Gastroenterology.* **2019**;157:692–704.e9. doi:10.1053/j.gastro.2019.05.007
35. McPhee F, Ueland J, Vellucci V, et al. Impact of preexisting hepatitis C virus genotype 6 NS3, NS5A, and NS5B polymorphisms on the in vitro potency of direct-acting antiviral agents. *Antimicrob Agents Chemother.* **2019**;63(4). doi:10.1128/AAC.00779-19
36. Cheng G, Tian Y, Doehle B, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. *Antimicrob Agents Chemother.* **2016**;60(3):1847–1853. doi:10.1128/AAC.02524-15
37. Dvory-Sobol H, Han B, Lu J, et al. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. *J Viral Hepat.* **2019**;26(8):991–1001. doi:10.1111/jvh.13116
38. Han B, Parhy B, Zhou E, et al. In vitro susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pan-genotypic NS3/4A inhibitor voxilaprevir. *J Clin Microbiol.* **2019**;57(4). doi:10.1128/JCM.01844-18
39. Sano T, Akuta N, Suzuki F, et al. Role of NS5A-L31/Y93 double wild-type in failure of glecaprevir/pibrentasvir double therapy in two patients with a history of direct-acting antiviral agent failure: an ultra-deep sequencing analysis. *Intern Med.* **2019**. doi:10.2169/internalmedicine.2604-18
40. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. *Hepatology.* **2014**;59(6):2083–2091. doi:10.1002/hep.27113
41. Harrington PR, Komatsu TE, Deming DJ, et al. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. *Hepatology.* **2018**;67(6):2430–2448. doi:10.1002/hep.29693
42. Xue W, Pan D, Yang Y, Liu H, Yao X. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. *Antiviral Res.* **2012**;93(1):126–137. doi:10.1016/j.antiviral.2011.11.007
43. Nguyen LT, Hall N, Sheerin D, Carr M, De Gascun CF. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. *Antivir Ther.* **2016**;21(5):447–453. doi:10.3851/IMP3025
44. Wu R, Chi X, Wang X, et al. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. *Infect Genet Evol.* **2016**;39:132–140. doi:10.1016/j.meegid.2016.01.020

45. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. *J Clin Virol*. 2013;57(1):13–18. doi:10.1016/j.jcv.2012.12.020
46. Peiffer KH, Sommer L, Susser S, et al. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. *Hepatology*. 2016;63(1):63–73. doi:10.1002/hep.28255
47. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). *Hepatology*. 2016;63(5):1430–1441. doi:10.1002/hep.28473
48. Bartolini B, Giombini E, Taibi C, et al. Characterization of naturally occurring NS5A and NS5B polymorphisms in patients infected with HCV genotype 3a treated with direct-acting antiviral agents. *Viruses*. 2017;9(8):212. doi:10.3390/v9080212
49. Walker A, Filke S, Lubke N, et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure. *Virol J*. 2017;14(1):106. doi:10.1186/s12985-017-0779-4
50. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. *Clin Infect Dis*. 2014;59(12):1666–1674. doi:10.1093/cid/ciu697
51. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. *Hepatology*. 2015;61(1):56–65. doi:10.1002/hep.27375
52. Hedskog C, Dvory-Sobol H, Gontcharova V, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. *J Viral Hepat*. 2015;22(11):871–881. doi:10.1111/jvh.12405
53. Peres-da-Silva A, Brandao-Mello CE, Lampe E. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV. *Antivir Ther*. 2017;22(5):447–451. doi:10.3851/IMP3131
54. Di Maio VC, Cento V, Lenci I, et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. *Liver Int*. 2017;37(4):514–528. doi:10.1111/liv.13327
55. Ito J, Suda G, Yamamoto Y, et al. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. *Hepatol Res*. 2016;46(13):1294–1303. doi:10.1111/hepr.12685
56. Dietz J, Susser S, Vermehren J, et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. *Gastroenterology*. 2018;154(4):976–988.e4. doi:10.1053/j.gastro.2017.11.007

## Infection and Drug Resistance

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress